acute myeloid leukemia

[Journal of Proteome Research] The authors performed an in-depth glycosphingolipid (GSL) glycan analysis of 19 AML cell lines using porous graphitized carbon liquid chromatography-mass spectrometry revealing strikingly different GSL glycan profiles between the various AML cell lines.

[Leukemia] To interrogate the effect of protein expression alterations in AML, researchers performed a quantitative mass spectrometry in parallel with RNAseq analysis using AML mouse models.

[Haematologica] Researchers designed a CD34/CD3 bispecific T-cell engager (BiTE) and characterized its anti-leukemia potential in vitro, ex vivo and in vivo.

[Blood] Scientists reported the results of a multicenter, open-label, Phase I/II study of flotetuzumab in 88 adults with relapsed/refractory AML: 42 in a dose-finding segment and 46 at the recommended Phase II dose of 500 ng/kg per day.

[Experimental Hematology] Investigators performed targeted panel sequencing of paired diagnostic and first treatment evaluation samples in 69 patients with residual disease by morphology or measurable residual disease level >0.02.

[Blood Advances] Researchers provided insight into the relapsed or refractory (R/R) AML molecular profile and the impact of FLT3 inhibitors on mutational evolution associated with treatment resistance and benefit of gilteritinib across a wide spectrum of molecular and genetic subgroups in FLT3-mutated R/R AML.